ATTR amyloidosis specialty market's blockbuster emergence — the transthyretin amyloid cardiomyopathy treatment market's extraordinary commercial trajectory — from a virtually nonexistent market before tafamidis's 2019 FDA approval toward a projected multi-billion dollar specialty pharmaceutical market whose growth is constrained primarily by diagnosis rates rather than treatment...